BridgeBio Oncology Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Basic Shares Outstanding (Weighted Average) of 80.05 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 80.05M shares, a 59.48% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 80.03K shares, a 80.32% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 79.99M shares, a 436894.09% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 43.49M shares, a 392100.24% increase year-over-year.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 80.05M shares 10-Q · filed 2026-08-11 | 80.07M shares 10-Q · filed 2026-08-11 | 53.37M shares derived: average of 3 quarters · filed 2026-08-11 | 50.90M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 80.03K shares 10-Q · filed 2026-05-12 | 40.03M shares derived: average of 2 quarters · filed 2026-05-12 | 41.19M shares derived: average of 3 quarters · filed 2026-05-12 | 43.44M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 79.99M shares 8-K · filed 2026-03-05 | 61.74M shares derived: average of 2 quarters · filed 2026-03-05 | 57.89M shares derived: average of 3 quarters · filed 2026-08-11 | 31.14M shares POS AM · filed 2026-04-30 |
| 2025-09-30 | 43.49M shares 10-Q · filed 2025-11-12 | 46.84M shares derived: average of 2 quarters · filed 2026-08-11 | 14.68M shares 10-Q · filed 2025-11-12 | 23.53M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 50.20M shares 10-Q · filed 2026-08-11 | 43.22M shares 10-Q · filed 2026-08-11 | 16.87M shares derived: average of 3 quarters · filed 2026-08-11 | 12.66M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 406.72K shares 10-Q · filed 2026-05-12 | 212.51K shares derived: average of 2 quarters · filed 2026-05-12 | 145.37K shares derived: average of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | 18.30K shares 8-K · filed 2026-03-05 | 14.70K shares derived: average of 2 quarters · filed 2026-03-05 | 12.90K shares POS AM · filed 2026-04-30 | |
| 2024-09-30 | 11.09K shares 10-Q · filed 2025-11-12 | 11.09K shares 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |